Rezipres Now Available for Intraoperative Hypotension
Rezipres is a ready-to-use formulation of injectable ephedrine hydrochloride.
Rezipres is a ready-to-use formulation of injectable ephedrine hydrochloride.
The new formulation is expected to save preparation time.
This week Pfizer seeks Emergency Use Authorization for their COVID-19 oral antiviral; A meta-analysis found commonly prescribed drugs were linked to orthostatic hypotension; A novel treatment is approved for polycythemia vera; A new program has been cleared to allow individuals to carry out remote endoscopy procedures; And the largest to date psilocybin trial shows promise in treatment-resistant depression.
The meta-analysis included 69 RCTs with a total of 27,079 patients.
Norepinephrine is a catecholamine indicated for restoration of blood pressure in adult patients with acute hypotensive states.
The phase 3 study was evaluating the efficacy and safety of ampreloxetine for the treatment of symptomatic neurogenic orthostatic hypotension in patients 30 years of age and older.
The FDA has approved Rezipres (ephedrine hydrochloride) for the treatment of clinically important hypotension occurring in the setting of anesthesia.
Within two to four months, increases, decreases in systolic BP seen in transmasculine, transfeminine adults, respectively
A non-integral crimped vial overseal may result in a non-sterile product.
Nexus Pharmaceuticals announced the launch of Emerphed™, a premixed, ready-to-use formulation of ephedrine.